Shenzhen Hepalink Pharmaceutical Group Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Shenzhen Hepalink Pharmaceutical Group Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 29 Nov 2017 | Lorem |
| Oncoquest open to CRO bids for Phase III ovarian cancer study, plans mezzanine USD 25m fundraise by 3Q17 - CEO | 08 Jun 2017 | Manasi Vaidya |
| OncoQuest uses CROs TFS and Veristat in ovarian cancer studies – exec | 28 Nov 2016 | Indrani Datta |
| Big CMOs to buy US biologics capabilities with a view to emerging market scale-out – experts | 13 Nov 2015 | Natalie Morrison |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer